The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with α-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with α-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with α-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

The present disclosure provides, inter alia, methods for treating diseases, e.g., a cancer, in a subject by targeting oncogenic lipids in cells, including increasing lipid-based reactive oxygen species (ROS) by inhibiting coenzyme Q.sub.10 (CoQ.sub.10) production. Methods for treating a subject with a cancer that is sensitive to an oncolipid-targeting therapy, e.g., ADCK3 inhibition, are also provided. Further provided are methods for modulating coenzyme Q.sub.10 (CoQ.sub.10) level in a subject, including determining CoQ.sub.10 levels by LC-MS.

The present disclosure provides, inter alia, methods for treating diseases, e.g., a cancer, in a subject by targeting oncogenic lipids in cells, including increasing lipid-based reactive oxygen species (ROS) by inhibiting coenzyme Q.sub.10 (CoQ.sub.10) production. Methods for treating a subject with a cancer that is sensitive to an oncolipid-targeting therapy, e.g., ADCK3 inhibition, are also provided. Further provided are methods for modulating coenzyme Q.sub.10 (CoQ.sub.10) level in a subject, including determining CoQ.sub.10 levels by LC-MS.

Provided is a liquid composition for ophthalmic products. The liquid composition includes a buffer solution and a zinc salt dissolved in the buffer solution. The zinc salt has a weight percentage concentration of 1×10.sup.−5% to 3% in the liquid composition. The liquid composition may also include a first vitamin dissolved in the buffer solution. The first vitamin has a weight percentage concentration of 1×10.sup.−5% to 1% in the liquid composition. The first vitamin includes vitamin B2, a vitamin B2 derivative, or a combination thereof.

Provided is a liquid composition for ophthalmic products. The liquid composition includes a buffer solution and a zinc salt dissolved in the buffer solution. The zinc salt has a weight percentage concentration of 1×10.sup.−5% to 3% in the liquid composition. The liquid composition may also include a first vitamin dissolved in the buffer solution. The first vitamin has a weight percentage concentration of 1×10.sup.−5% to 1% in the liquid composition. The first vitamin includes vitamin B2, a vitamin B2 derivative, or a combination thereof.

Disclosed are methods and compositions for treating ore preventing a STAT5-mediated medical condition, e.g., rheumatoid arthritis, in a subject by administering to the subject a therapeutically effective amount of a compound, the compound being a STAT5 inhibitor, or a pharmaceutically acceptable salt of the STAT5 inhibitor, or a solvate of the STAT5 inhibitor, or a prodrug of the STAT5 inhibitor. In one example, the compound used in the methods and compositions is pimozide. In another example, the compound used in the methods and compositions is nicotinohydrazide.